SCHEMBL16945312

SCHEMBL16945312

CCOc1cccc(CNC(=O)c2c(C)nc3sc(C)cn23)c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 3/20 0.51
ROCK2 O75116 2/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
MAPT P10636 4/20 0.49
TP53 P04637 2/20 0.49
POLB P06746 2/20 0.46
KLKB1 P03952 2/20 0.46
KLK1 P06870 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
HPGD P15428 1/20 0.45
KMT2A Q03164 1/20 0.45
KDM4E B2RXH2 1/20 0.45
LMNA P02545 1/20 0.45
PKM P14618 1/20 0.45
HTT P42858 1/20 0.45
THRB P10828 2/20 0.43
RXFP1 Q9HBX9 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16945273 0.90 LMNA (0.54) ROCK1ROCK2CYP3A4CYP2D6CYP2C9
SCHEMBL16945304 0.89 LMNA (0.51) MAPTTP53POLBSMN1; SMN2KDM4E
SCHEMBL16945305 0.88 LMNA (0.45) ROCK1ROCK2MAPTTP53POLB
SCHEMBL16945283 0.86 MAPK14 (0.53) ROCK1ROCK2
SCHEMBL16945336 0.85 MMP13 (0.46) CYP3A4MAPTTP53SMN1; SMN2KDM4E
SCHEMBL16945335 0.85 PPARG (0.46) CYP3A4MAPTSMN1; SMN2HPGDKMT2A
SCHEMBL16945269 0.84 SCD (0.50) MAPTTP53SMN1; SMN2KDM4ELMNA
SCHEMBL16945280 0.84 KMT2A (0.52) MAPTTP53SMN1; SMN2KMT2ALMNA
SCHEMBL16945276 0.84 LMNA (0.53) MAPTPOLBSMN1; SMN2HPGDKDM4E
SCHEMBL24003414 0.83 SMN1; SMN2 (0.44) ROCK1ROCK2SMN1; SMN2KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2875029-B1 5,5-HETEROAROMATIC ANTI-INFECTIVE COMPOUNDS MORASKI GARRETT (US) 2021-11-10 EP disclosed
US-9605002-B2 5,5-heteroaromatic anti-infective compounds UNIVERSITY OF NOTRE DAME DU LAC (US) 2017-03-28 US disclosed
US-9605002-B2 5,5-heteroaromatic anti-infective compounds UNIVERSITY OF NOTRE DAME DU LAC (US) 2017-03-28 US disclosed
US-20150210715-A1 5,5-HETEROAROMATIC ANTI-INFECTIVE COMPOUNDS UNIVERSITY OF NOTRE DAME DU LAC 2015-07-30 US disclosed
US-20150210715-A1 5,5-HETEROAROMATIC ANTI-INFECTIVE COMPOUNDS UNIVERSITY OF NOTRE DAME DU LAC 2015-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210715-A1 5,5-HETEROAROMATIC ANTI-INFECTIVE COMPOUNDS API5, CASP5, IL5 ROCK1 3420/4885ROCK2 3440/4885CYP3A4 1125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.